Question explored with the scientific record
Conversation so far
- 1 What does long term pregabalin use do to you?
- 2 What withdrawal symptoms and timeline are reported after stopping?
- 3 Are there safer alternatives to pregabalin that lower withdrawal risk?
Answered on this page ↓
Are there safer alternatives to pregabalin that lower withdrawal risk?
The short version: the evidence does not answer whether any alternative lowers pregabalin withdrawal risk, because none of these studies tested that question.
The evidence you have is a pile of studies about other drugs and other conditions. One case report describes a patient on pregabalin who developed hypomania when venlafaxine was stopped, but that tells you nothing about whether switching to duloxetine or another drug makes pregabalin withdrawal easier [2]. A 2022 review says duloxetine 60 mg works for fibromyalgia pain and amitriptyline helps sleep, but neither study measured what happens when you stop pregabalin and start them [9]. The duloxetine withdrawal data shows that drug has its own discontinuation syndrome: dizziness in 12.4% of patients, nausea in 5.9% [6]. Switching from one dependence-producing drug to another does not eliminate withdrawal, it trades one withdrawal profile for another.
The most honest answer is that no study in this retrieval compared tapering strategies or alternative medications for pregabalin discontinuation. The manufacturer-funded trials report dizziness and somnolence during treatment [3, 4] but do not report what happens when the drug is stopped. The question you are asking was never studied in the evidence here.
My call: there is no evidence in this retrieval that any alternative pharmacotherapy lowers pregabalin withdrawal risk. Confidence: low, because the question was not tested.
Sources examined 18
-
Neuropsychiatric symptoms accompanying thrombocytopenia following pregabalin treatment for neuralgia: a case report
This case report describes a 28-year-old female patient who developed neuropsychiatric symptoms and thrombocytopenia following pregabalin treatment for neuralgia, highlighting the need for careful monitoring of patients on this medication.
DOI: 10.1007/s11096-014-0026-7 -
Hypomanic Episode Upon Venlafaxine Discontinuation
This case report documents a hypomanic switch occurring during slow discontinuation of venlafaxine in a 48-year-old woman with a history of recurrent depression, highlighting a potential antidepressant-discontinuation–associated mood change and the need for further study.
DOI: 10.1016/s0924-9338(15)30913-5 -
Long-term safety and tolerability of pregabalin treatment in three open-label extension studies in patients with fibromyalgia
A pooled analysis of pregabalin trials in fibromyalgia shows meaningful improvements in fatigue, function, and self-reported presenteeism at 450 mg/day, with supportive long-term safety data from open-label extensions, and supplementary analyses on milnacipran's PGIC relationshi…
DOI: 10.1016/j.jpain.2009.01.303 -
Pregabalin relieves symptoms of painful diabetic neuropathy
A multicenter, randomized, double-blind, placebo-controlled trial demonstrating that pregabalin at 300 and 600 mg/day provides early and sustained relief of pain and sleep interference in diabetic peripheral neuropathy, with the 75 mg/day dose being ineffective and pregabalin ge…
DOI: 10.1212/01.wnl.0000145767.36287.a1 -
Duloxetine Withdrawal Syndrome in a Newborn
This case report describes a full-term infant girl who exhibited symptoms consistent with withdrawal syndrome from in utero exposure to duloxetine, highlighting the need for further research on the effects of SNRIs during pregnancy.
DOI: 10.1177/0009922812450509 -
Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder
This study characterizes the discontinuation-emergent adverse events (DEAEs) associated with abrupt cessation of duloxetine treatment in patients with major depressive disorder, revealing a significant incidence of symptoms such as dizziness, nausea, and headache.
DOI: 10.1016/j.jad.2005.09.003 -
Fecal Microbiota Transplantaion in the treatement of mood disorders : A literature review
A clinical case report of severe hyperhidrosis induced by bupropion in a 42-year-old woman with recurrent major depressive disorder, successfully managed by gradual withdrawal and switching to duloxetine with improved quality of life and stable mood.
DOI: 10.1192/j.eurpsy.2024.663 -
A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder
An 8-week randomized, double-blind, placebo-controlled trial in elderly patients with major depressive disorder showed Lu AA21004 at 5 mg/day to be superior to placebo on depressive symptoms and cognitive measures, with duloxetine as an active reference and overall good tolerabi…
DOI: 10.1097/YIC.0b013e3283542457 -
Fibromyalgia syndrome: epidemiology, diagnosis and treatment
Fibromyalgia syndrome is a common chronic pain disorder with evolving diagnostic criteria and multimodal management integrating drugs like pregabalin and duloxetine with exercise, CBT, and education.
DOI: 10.5114/reum.2022.123671 -
Generalized Tonic-Clonic Seizures Following Withdrawal of Therapeutic Dose of Bromazepam
This case study presents a detailed account of a 56-year-old woman who experienced generalized tonic-clonic seizures following the abrupt withdrawal of bromazepam, highlighting the potential risks associated with discontinuing benzodiazepine treatment in patients with a history …
DOI: 10.1055/s-2007-979188 -
Psychometric Evaluation of the Sophia Observation Withdrawal Symptoms Scale in Critically Ill Children
This study evaluates the psychometric properties of the Sophia Observation Withdrawal Symptoms Scale for assessing withdrawal symptoms in critically ill children receiving prolonged sedation with benzodiazepines and/or opioids, establishing cutoff scores and identifying risk fac…
DOI: 10.1097/PCC.0b013e31829f5be1 -
High doses of benzodiazepine predict analgesic and sedative drug withdrawal syndrome in paediatric intensive care patients
This study evaluates the incidence of withdrawal syndrome in critically ill children after prolonged analgesic and sedative therapy, finding a 37% incidence associated with high doses of benzodiazepines.
DOI: 10.1111/apa.12777 -
Propofol for Treatment of Refractory Alcohol Withdrawal Syndrome: A Review of the Literature
This literature review synthesizes available evidence on propofol as an adjunct to benzodiazepines for treating refractory alcohol withdrawal syndrome in adults, highlighting potential benzodiazepine-sparing benefits alongside risks (notably hypotension and respiratory depressio…
DOI: 10.1002/phar.1726 -
Patient, Process, and System Predictors of Iatrogenic Withdrawal Syndrome in Critically Ill Children*
This study identifies patient, process, and system-level predictors of iatrogenic withdrawal syndrome in critically ill children, highlighting the commonality of this condition and the importance of recognizing risk factors to improve prevention strategies.
DOI: 10.1097/CCM.0000000000001953 -
Tolerance and addiction; the patient, the parent or the clinician?
This article provides a narrative review of tolerance and withdrawal phenomena related to opioids, benzodiazepines, and other sedatives in pediatric perioperative, neonatal, and critical care settings, summarizing mechanisms, clinical implications, assessment tools (WAT-1, SOS),…
DOI: 10.1111/j.1460-9592.2010.03501.x -
Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
A comprehensive literature overview applying Chouinard and Chouinard's withdrawal criteria to discontinue/discontinue-like changes in psychotropic medications across drug classes, detailing the types, onset, duration, and systemic implications of new withdrawal symptoms, rebound…
DOI: 10.1159/000506868 -
Impact of Early Reinitiation of Neuropsychiatric Medications on Agitation and Delirium in the Intensive Care Unit: A Retrospective Study
Retrospective, single-center cohort study evaluating whether early reinitiation (within 72 hours) of home neuropsychiatric medications (NPMs) in ICU patients reduces agitation or delirium; unadjusted analyses suggested fewer agitation/delirium and shorter ICU/hospital stays with…
DOI: 10.1177/1060028020935589 -
Lorazepam: Effects on Sleep and Withdrawal Phenomena
This study evaluates the effects of lorazepam on sleep induction and maintenance, revealing moderate effectiveness during administration but significant rebound insomnia and increased anxiety following withdrawal.
DOI: 10.1159/000138160